Drug intelligence / Profile preview

Oralgen House Dust Mite

Development stage: Unknown
Lead developer: ALK Abelló
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Oral

Overview

Oralgen House Dust Mite is an investigational oral immunotherapy (OIT) product developed by Artu Biologicals Europe B.V. for the treatment of house dust mite-induced allergic rhinoconjunctivitis. It is a biological allergen extract derived from the antigens of house dust mites, specifically *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. The product is administered orally to induce immune tolerance by modulating the patient's aberrant IgE-mediated immune response. It has been evaluated in a Phase I/IIa double-blind, randomized, placebo-controlled dose-escalation study to assess its safety, tolerability, and preliminary efficacy in adult patients.

Brand names: Oralgen Mijten
Other names: HDM-SLIThouse dust mite allergen extractDermatophagoides pteronyssinus extract

Targets

House dust mite allergen-specific CD4+ T-cell receptorBCR (Immunoglobulin G B Cell Receptor)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)sIgG4 (Allergen-specific immunoglobulin G4)

Beyond the preview

Go deeper on Oralgen House Dust Mite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oralgen House Dust Mite.

Explore the full profile